ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Oncology · Cancer · 2025-12-15

Meta-analysis of 17 studies (10,396 adults) of allo-HSCT for blood cancers: fludarabine-melphalan vs fludarabine-busulfan was associated with better PFS (HR 0.90) and less relapse but higher treatment-related mortality (HR 1.44); OS did not differ.

Meta-analysisn = 10,396
Wannaphut et al. Outcomes of fludarabine-melphalan versus fludarabine-busulfan reduced-intensity conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies: A systematic review and meta-analysis
Transplantation · Transplant Cell Ther · 2025-12-03

Meta-analysis of 5 RCTs (975 adults) having myeloablative allo-HSCT: busulfan/fludarabine was associated with lower 1-year non-relapse mortality than busulfan/cyclophosphamide (RR 0.49; 2 trials) and fewer grade 3-5 events, with no difference in overall mortality.

Meta-analysisn = 975
Shimada et al. Comparison of Myeloablative Busulfan/Cyclophosphamide and Busulfan/Fludarabine for Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.